Appili to conduct clinical trials of Avigan in North America

By The Science Advisory Board staff writers

October 30, 2020 -- Appili Therapeutics has signed an agreement with Dr. Reddy's Laboratories and Global Response Aid to coordinate and accelerate worldwide development, commercialization, and distribution of favipiravir (Avigan) for the treatment of COVID-19.

Avigan is a broad-spectrum antiviral in oral tablet form. It is approved in Japan as a treatment and stockpile countermeasure for pandemic influenza.

Appili will assume responsibilities for the design and implementation of global clinical programs and related work for multiple phase III trials to support regulatory submissions of the drug for treatment or prevention of COVID-19 in the U.S., Canada, and internationally. The studies will focus on early treatment and postexposure prophylaxis.

The announcement follows a previous global licensing transaction between Dr. Reddy's, Global Response Aid, and Fujifilm Toyama Chemical, the originator of Avigan. Dr. Reddy's and Global Response Aid will continue to be responsible for the research and development, manufacturing, commercialization, and distribution of Avigan. Fujifilm will provide its knowledge base, including clinical data and intellectual property.

Appili will receive a profit share on all U.S. and Canadian sales for a specified term, and the company will be eligible to receive royalties on sales in Europe and Latin America for a specified term.

Validating drug repurposing workflows may help identify new COVID-19 treatments
A research team has strengthened COVID-19 drug repurposing workflows through independent in vitro validation followed by clinical pharmacology data assessments,...
Study investigates pharmacogenomics of COVID-19 therapies
Human genetic variation may alter the interactions of drugs being used to treat patients with COVID-19 symptoms, resulting in a range of clinical responses...
New repository may speed COVID-19 drugs to market
As researchers race to find vaccines and treatments for COVID-19, drug repurposing has emerged as potentially the fastest route to get drugs to market....
Glenmark begins phase III trials for favipiravir
Glenmark has launched phase III clinical trials in India to assess the use of its favipiravir antiviral tablets on COVID-19 patients. The drug is a generic...
Researchers call for rapid drug repurposing to fight COVID-19
Filling the therapeutic gap for coronavirus treatments with existing drugs approved for other uses could greatly benefit patients around the world. Researchers...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter